Medical weightloss
2 min read

Retatrutide: A new approach to weight loss

Retatrutide: veelbelovende nieuwe ontwikkeling voor de aanpak van overgewicht en obesitas
Go to overview

At The Body Clinic, we are always at the forefront of innovations in the world of Medical Weight Loss.

At The Body Clinic, we are always at the forefront of innovations in the world of Medical Weight Loss. One of the latest developments currently receiving much attention is Retatrutide. This drug, developed by Eli Lilly, is expected to be the next step in addressing and treating overweight and obesity. However, Retatrutide has not yet been approved by European and Dutch authorities and is therefore not yet available as a treatment.

What is Retatrutide?

Retatrutide is a once-weekly injectable medication that affects multiple hormone receptors in the body. Preliminary research results show promising effects on weight loss in people with overweight or obesity. The drug is a so-called tri-agonist, meaning it simultaneously stimulates three different hormone receptors:

  1. GLP-1: Lowers appetite and improves blood sugar levels;
  2. GIP: Stimulates insulin release and can help reduce fat mass;
  3. Glucagon: Increases energy expenditure and promotes fat metabolism.

Eli Lilly

Eli Lilly is a leading pharmaceutical company, founded in 1876 in the United States. They focus on developing innovative medicines for global health problems. They are known for their focus on scientific research, which has led them to find treatments for diabetes, oncology, immunology, and obesity management.

The Obesity Pandemic

Retatrutide is being developed in response to the obesity pandemic. Obesity is a complex chronic disease often accompanied by other ailments such as type II diabetes, high blood pressure, and cardiovascular diseases. If approved, Retatrutide could potentially contribute to the management of overweight and obesity.

The Future of Retatrutide

Retatrutide is in the final phase of clinical trials and is therefore not yet available. The Body Clinic is closely monitoring the progress of Retatrutide, and if the medication is approved, we will be able to offer more information on it. Do you have a BMI of ≥27 with a weight-related condition or a BMI of ≥30 and are you curious about the possibilities already available in the field of Medical Weight Loss? Then schedule a free intake with one of our doctors.

none provided
Michiel van LeeuwenMedical weight loss coach

With my years of experience in the pharmaceutical industry and my work on the development of anti-obesity medication, I understand better than anyone how complex weight problems are. It goes beyond willpower – it is a medical condition that requires an integrated approach. I strongly believe in promoting healthy lifestyle habits and offering support to people struggling with obesity. Medication can be a powerful aid, but real change occurs when we combine this with sustainable adjustments in your daily life. Through online guidance, I help you achieve and maintain a healthy weight – with attention to both medication and learning and normalizing a healthy lifestyle. Because lasting results start with an approach that suits you. Michiel completed his medical training at Vrije Universiteit Amsterdam, where he also completed his doctoral research in experimental and plastic surgery, focusing on wound healing and stem cell technology. His unique combination of academic knowledge, pharmaceutical expertise, and clinical experience in addiction care and cosmetic medicine makes him a versatile specialist in medical weight loss.

Related articles

Medical weightloss
Saxenda zonder verwijzing van de huisarts: kies voor specialistische begeleiding bij The Body Clinic
Saxenda at GP

Dec 12, 2025

Medical weightloss
Client wordt gewogen tijdens medisch afvallen traject bij The Body Clinic
none provided
Losing weight isn’t working out? Prevent a relapse!

May 9, 2025

Medical weightloss
Client toont buik bij informatieve content over Survodutide en medisch afvallen bij The Body Clinic
none provided
Survodutide, possibly a new treatment for obesity

Feb 14, 2025